De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Grifols Beheer

Beheer criteriumcontroles 2/4

De CEO Grifols' is Nacho Abia Buenache, benoemd in Apr2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde $ 972.78K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 6.9 jaar.

Belangrijke informatie

Nacho Abia Buenache

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	6.9yrs

Recente managementupdates

Recent updates

CEO

Nacho Abia Buenache (56 yo)

less than a year

Tenure

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jose Ignacio Abia Buenache	CEO & Director	less than a year	geen gegevens	0.014% $ 927.8k
Alfredo Guerra	CFO & VP	17.8yrs	geen gegevens	geen gegevens
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	geen gegevens	geen gegevens
Nuria Lapeña	VP of Corporate Treasury	no data	geen gegevens	geen gegevens
David Bell	Chief Corporate Development	21.8yrs	geen gegevens	0.0029% $ 199.7k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	geen gegevens	0.00078% $ 53.0k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	geen gegevens	geen gegevens
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	geen gegevens	geen gegevens
Sergio Adell	President of Commercial Tech Support	5.8yrs	geen gegevens	geen gegevens
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% $ 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	geen gegevens	geen gegevens
Daniel Coit	Chief Industrial Services Officer	5.8yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GIFO.F is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jose Ignacio Abia Buenache	CEO & Director	less than a year	geen gegevens	0.014% $ 927.8k
Víctor Grifols Deu	Executive Director	8.4yrs	€1.04m	0.016% $ 1.1m
Iñigo Mardones	Independent Director	9.4yrs	€150.00k	geen gegevens
Thomas Glanzmann	Non-Executive Chairman	18.5yrs	€1.90m	0.029% $ 2.0m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	geen gegevens
Raimon Grifols Roura	Vice-Chairman	9.4yrs	€1.04m	0.0060% $ 410.9k
Tomas Daga Gelabert	Independent External Director	24.5yrs	geen gegevens	0.045% $ 3.0m
Albert Coma-Cros	Proprietary Director	less than a year	geen gegevens	0.0097% $ 659.5k
Enriqueta Font	Independent Director	5.4yrs	€125.00k	geen gegevens
Montserrat Abellana	Lead Independent Director	2.3yrs	€63.00k	geen gegevens
Susana Gonzalez Rodriguez	Independent Director	2.3yrs	€63.00k	geen gegevens
Anne-Catherine Berner	Independent Director	less than a year	geen gegevens	geen gegevens

6.9yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GIFO.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).

Grifols Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Recent updates

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd